Mologic and Alamar team up to fight future threats from Covid

Mologic in Bedford UK and Maine in the US and Alamar Biosciences in California are partnering on the project.

The collaboration will utilise Alamar’s novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.

Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (COVIOS and COVIGO for personal self-testing) based on its lateral flow assay technology, utilising high affinity, paired antibodies specific for the SARS-CoV-2 nucleoprotein antigen.  Read more

Related Posts

On the Record: Roux Institute’s Lars Perkins helps startups take off

Lars Perkins, a former software entrepreneur, Google executive and certified flight instructor who once flew planes for lifesaving “adventure philanthropy,” is managing...

28 November 2022

UNE to begin building new medical school at Portland campus

The University of New England is about to start a $93 million project to move the state’s only medical school from...

28 November 2022

Portland Planning Board recommends zoning changes for Roux Institute redevelopment

The Portland Planning Board is recommending that the city adopt zoning changes requested by the developers of a new graduate school...

22 November 2022